Utomilumab is currently being evaluated in a phase 1b/3 study in combination with anti-PD-L1 avelumab, anti-CD20 rituximab and conventional chemotherapy in R/R DLBCL (NCT02951156). The gene discussed is CD274; the disease is diffuse large B-cell lymphoma.